| Meeting the challenge of targeting cancer stem cells A Turdo, V Veschi, M Gaggianesi, A Chinnici, P Bianca, M Todaro, ... Frontiers in cell and developmental biology 7, 16, 2019 | 149 | 2019 |
| CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2 L Chen, G Alexe, NV Dharia, L Ross, AB Iniguez, AS Conway, EJ Wang, ... The Journal of clinical investigation 128 (1), 446-462, 2018 | 147 | 2018 |
| Epigenetic siRNA and chemical screens identify SETD8 inhibition as a therapeutic strategy for p53 activation in high-risk neuroblastoma V Veschi, Z Liu, TC Voss, L Ozbun, B Gryder, C Yan, Y Hu, A Ma, J Jin, ... Cancer cell 31 (1), 50-63, 2017 | 102 | 2017 |
| Targeting MYCN in Pediatric and Adult Cancers Z Liu, SS Chen, S Clarke, V Veschi, CJ Thiele Frontiers in Oncology 10, 623679, 2021 | 85 | 2021 |
| PI3K-driven HER2 expression is a potential therapeutic target in colorectal cancer stem cells LR Mangiapane, A Nicotra, A Turdo, M Gaggianesi, P Bianca, S Di Franco, ... Gut 71 (1), 119-128, 2022 | 75 | 2022 |
| Microenvironment in neuroblastoma: isolation and characterization of tumor-derived mesenchymal stromal cells G Pelizzo, V Veschi, M Mantelli, S Croce, V Di Benedetto, P D’Angelo, ... BMC cancer 18, 1-12, 2018 | 73 | 2018 |
| Inhibition of STAT3 with the Generation 2.5 Antisense Oligonucleotide, AZD9150, Decreases Neuroblastoma Tumorigenicity and Increases Chemosensitivity S Odate, V Veschi, S Yan, N Lam, R Woessner, CJ Thiele Clinical Cancer Research 23 (7), 1771-1784, 2017 | 68 | 2017 |
| Adipose stem cell niche reprograms the colorectal cancer stem cell metastatic machinery S Di Franco, P Bianca, DS Sardina, A Turdo, M Gaggianesi, V Veschi, ... Nature communications 12 (1), 5006, 2021 | 65 | 2021 |
| Cancer stem cells and neuroblastoma: characteristics and therapeutic targeting options V Veschi, F Verona, CJ Thiele Frontiers in endocrinology 10, 782, 2019 | 48 | 2019 |
| MYCN sensitizes human neuroblastoma to apoptosis by HIPK2 activation through a DNA damage response M Petroni, V Veschi, A Prodosmo, C Rinaldo, I Massimi, M Carbonari, ... Molecular Cancer Research 9 (1), 67-77, 2011 | 48 | 2011 |
| Cancer stem cells in thyroid tumors: from the origin to metastasis V Veschi, F Verona, M Lo Iacono, C D'Accardo, G Porcelli, A Turdo, ... Frontiers in Endocrinology 11, 566, 2020 | 39 | 2020 |
| The MRN complex is transcriptionally regulated by MYCN during neural cell proliferation to control replication stress M Petroni, F Sardina, C Heil, M Sahún-Roncero, V Colicchia, V Veschi, ... Cell Death & Differentiation 23 (2), 197-206, 2016 | 39 | 2016 |
| CHK1 inhibitor sensitizes resistant colorectal cancer stem cells to nortopsentin S Di Franco, B Parrino, M Gaggianesi, VD Pantina, P Bianca, A Nicotra, ... Iscience 24 (6), 2021 | 38 | 2021 |
| Messing up the cancer stem cell chemoresistance mechanisms supported by tumor microenvironment M Gaggianesi, S Di Franco, VD Pantina, G Porcelli, C D'Accardo, ... Frontiers in Oncology 11, 702642, 2021 | 33 | 2021 |
| Nobiletin and xanthohumol sensitize colorectal cancer stem cells to standard chemotherapy A Turdo, A Glaviano, G Pepe, F Calapà, S Raimondo, ME Fiori, ... Cancers 13 (16), 3927, 2021 | 31 | 2021 |
| Galectin-3 impairment of MYCN-dependent apoptosis-sensitive phenotype is antagonized by nutlin-3 in neuroblastoma cells V Veschi, M Petroni, B Cardinali, C Dominici, I Screpanti, L Frati, ... PloS one 7 (11), e49139, 2012 | 29 | 2012 |
| Molecular mechanisms of MYCN-dependent apoptosis and the MDM2–p53 pathway: an Achille’s heel to be exploited for the therapy of MYCN-amplified neuroblastoma M Petroni, V Veschi, A Gulino, G Giannini Frontiers in oncology 2, 141, 2012 | 29 | 2012 |
| Human papilloma virus-dependent HMGA1 expression is a relevant step in cervical carcinogenesis M Mellone, C Rinaldi, I Massimi, M Petroni, V Veschi, C Talora, S Truffa, ... Neoplasia 10 (8), 773-781, 2008 | 29 | 2008 |
| Targeting chemoresistant colorectal cancer via systemic administration of a BMP7 variant V Veschi, LR Mangiapane, A Nicotra, S Di Franco, E Scavo, T Apuzzo, ... Oncogene 39 (5), 987-1003, 2020 | 28 | 2020 |
| The HMGA1 protoncogene frequently deregulated in cancer is a transcriptional target of E2F1 I Massimi, F Guerrieri, M Petroni, V Veschi, S Truffa, I Screpanti, L Frati, ... Molecular Carcinogenesis 52 (7), 526-534, 2013 | 25 | 2013 |
